Topoisomerase IIα, rather than II β, is a promising target in development of anticancer drugs

Drug Discoveries & Therapeutics

Volumn 6, Issue 5, 2011, Pages 230-237

  Chen, Wang ^a   Qiu, Jin ^a,b   Shen, Yuemao ^a  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Cancer therapy; Inhibitors; Therapeutic target; Topoisomerase II

Indexed keywords

EID: 85008737005     PISSN: 18817831     EISSN: 1881784X     Source Type: Journal    
DOI: 10.5582/ddt.2012.v6.5.230     Document Type: Article

References (58)

1. Azarova AM, Lyu YL, Lin CP, Tsai YC, Lau JY, Wang JC, Liu LF. Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies. Proc Natl Acad Sci U S A. 2007; 104:11014-11019.
2. Toyoda E, Kagaya S, Cowell IG, Kurosawa A, Kamoshita K, Nishikawa K, Iiizumi S, Koyama H, Austin CA, Adachi N. NK314, a topoisomerase II inhibitor that specifically targets the α isoform. J Biol Chem. 2008; M803936200.
3. Schoeffler AJ, Berger JM. DNA topoisomerases: Harnessing and constraining energy to govern chromosome topology. Q Rev Biophys. 2008; 41:41-101.
4. Corbett KD, Berger JM. Structure of the topoisomerase VI-B subunit: Implications for type II topoisomerase mechanism and evolution. EMBO J. 2003; 22:151-163.
5. Wang JC. Interaction between DNA and an Escherichia coli protein omega. J Mol Biol. 1971; 55:523-533.
6. Tesauro C, Fiorani P, D'Annessa I, Chillemi G, Turchi G, Desideri A. Erybraedin C, a natural compound from the plant Bituminaria bituminosa, inhibits both the cleavage and religation activities of human topoisomerase I. Biochem J. 2010; 425:531-539.
7. Peterson KE, Cinelli MA, Morrell AE, Mehta A, Dexheimer TS, Agama K, Antony S, Pommier Y, Cushman M. Alcohol-, diol-, and carbohydrate-substituted indenoisoquinolines as topoisomerase I inhibitors: Investigating the relationships involving stereochemistry, hydrogen bonding, and biological activity. J Med Chem. 2011; 54:4937-4953.
8. Dong KC, Berger JM. Structural basis for gate-DNA recognition and bending by type IIA topoisomerases. Nature. 2007; 450:1201-1205.
9. Wang JC. Cellular roles of DNA topoisomerases: A molecular perspective. Nat Rev Mol Cell Biol. 2002; 3:430-440.
10. Li TK, Liu LF. Tumor cell death induced by topoisomerase-targeting drugs. Annu Rev Pharmacol Toxicol. 2001; 41:53-77.
11. Wu CC, Li TK, Farh L, Lin LY, Lin TS, Yu YJ, Yen TJ, Chiang CW, Chan NL. Structural basis of type II topoisomerase inhibition by the anticancer drug etoposide. Science. 2011; 333:459-462.
12. Austin CA, Sng JH, Patel S, Fisher LM. Novel HeLa topoisomerase II is the II β isoform: Complete coding sequence and homology with other type II topoisomerases. Biochim Biophys Acta. 1993; 1172:283-291.
13. Jenkins JR, Ayton P, Jones T, Davies SL, Simmons DL, Harris AL, Sheer D, Hickson ID, Isolation of cDNA clones encoding the β isozyme of human DNA topoisomerase II and localisation of the gene to chromosome 3p24. Nucleic Acids Res. 1992; 20:5587-5592.
14. Woessner RD, Mattern MR, Mirabelli CK, Johnson RK, Drake FH. Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell Growth Differ. 1991; 2:209-214.
15. Meresse P, Dechaux E, Monneret C, Bertounesque E. Etoposide: Discovery and medicinal chemistry. Curr Med Chem. 2004; 11:2443-2466.
16. Long BH. Mechanisms of action of teniposide (VM-26) and comparison with etoposide (VP-16). Semin Oncol. 1992; 19:3-19.
17. De Beer EL, Bottone AE, Voest EE. Doxorubicin and mechanical performance of cardiac trabeculae after acute and chronic treatment: A review. Eur J Pharmacol. 2001; 415:1-11.
18. Wallace KB. Doxorubicin-induced cardiac mitochondrionopathy. Pharmacol Toxicol. 2003; 93:105-115.
19. Zucchi R,Danesi R. Cardiac toxicity of antineoplastic anthracyclines. Curr Med Chem Anticancer Agents. 2003; 3:151-171.
20. Xu X, Persson HL, Richardson DR. Molecular pharmacology of the interaction of anthracyclines with iron. Mol Pharmacol. 2005; 68:261-271.
21. Lyu YL, Kerrigan JE, Lin CP, Azarova AM, Tsai YC, Ban Y, Liu LF. Topoisomerase II mediated DNA double-strand breaks: Implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Cancer Res. 2007; 67:8839-8846.
22. Holmes FA, Yap HY, Esparza L, Buzdar AU, Hortobagyi GN, Blumenschein GR. Mitoxantrone, cyclophosphamide, and 5-fluorouracil in the treatment of hormonally unresponsive metastatic breast cancer. Semin Oncol. 1984; 11:28-31.
23. Velasquez WS, Lew D, Grogan TM, Spiridonidis CH, Balcerzak SP, Dakhil SR, Miller TP, Lanier KS, Chapman RA, Fisher RI. Combination of fludarabine and mitoxantrone in untreated stages III and IV low-grade lymphoma: S9501. J Clin Oncol. 2003; 21:1996-2010.
24. Lown JW, Morgan AR, Yen SF, Wang YH, Wilson WD. Characteristics of the binding of the anticancer agents mitoxantrone and ametantrone and related structures to deoxyribonucleic acids. Biochemistry. 1985; 24:4028-4035.
25. Krishnamoorthy CR, Yen SF, Smith JC, Lown JW, Wilson WD. Stopped-flow kinetic analysis of the interaction of anthraquinone anticancer drugs with calf thymus DNA, poly[d(G-C)].poly[d(G-C)], and poly[d(A-T)]. poly[d(A-T)]. Biochemistry. 1986; 25:5933-5940.
26. Fortune JM, Osheroff N. Topoisomerase II as a target for anticancer drugs: When enzymes stop being nice. Prog Nucleic Acid Res Mol Biol. 2000; 64:221-253.
27. Giles GI, Sharma RP. Topoisomerase enzymes as therapeutic targets for cancer chemotherapy. Med Chem. 2005; 1:383-394.
28. Osheroff N. Effect of antineoplastic agents on the DNA cleavage/religation reaction of eukaryotic topoisomerase II: inhibition of DNA religation by etoposide. Biochemistry. 1989; 28:6157-6160.
29. Nitiss JL, Wang JC. Mechanisms of cell killing by drugs that trap covalent complexes between DNA topoisomerases and DNA. Mol Pharmacol. 1996; 50:1095-1102.
30. Richards AD, Rodger A. Synthetic metallomolecules as agents for the control of DNA structure. Chem Soc Rev. 2007; 36:471-483.
31. Speyer JL, Green MD, Kramer E, Rey M, Sanger J, Ward C, Dubin N, Ferrans V, Stecy P, Zeleniuch-Jacquotte A. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N Engl J Med. 1988; 319:745-752.
32. McClendon AK, Osheroff N. DNA topoisomerase II, genotoxicity, and cancer. Mutat Res. 2007; 623:83-97.
33. Bender RP, Osheroff N. DNA Topoisomerases as targets for the chemotherapeutic treatment of cancer. In: Cancer Drug Discovery and Development. Checkpoint Responses in Cancer Therapy (Dai W, ed.). Humana Press, New York, NY, USA, 2008; pp. 57-91.
34. Martincic D, Hande KR. Topoisomerase II inhibitors. Cancer Chemother Biol Response Modif. 2005; 22:101-121.
35. Whitnall M, Howard J, Ponka P, Richardson DR. A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc Natl Acad Sci U S A. 2006; 103:14901-14906.
36. Yuan J, Lovejoy DB, Richardson DR. Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: In vitro and in vivo assessment. Proc Natl Acad Sci U S A. 2006; 103:14901-14906.
37. Toyoda E, Kagaya S, Cowell IG, Kurosawa A, Kamoshita K, Nishikawa K, Iiizumi S, Koyama H, Austin CA, Adachi N. NK314, a topoisomerase II inhibitor that specifically targets the isoform. Blood. 2004; 104:1450-1458.
38. Guo L, Liu X, Jiang Y, Nishikawa K, Plunkett W. DNA dependent protein kinase and ataxia telangiectasia mutated (ATM) promote cell survival in response to NK314, a topoisomerase IIα inhibitor. Mol Pharmacol. 2011; 80:321-327.
39. Du L, Liu HC, Fu W, Li DH, Pan QM, Zhu TJ, Geng MY, Gu QQ. Unprecedented citrinin trimer tricitinol B functions as a novel topoisomerase IIα inhibitor. J Med Chem. 2011; 54:5796-5810.
40. Horstmann MA, Hassenpflug WA, zur Stadt U, Escherich G, Janka G, Kabisch H. Amsacrine combined with etoposide and high-dose methylprednisolone as salvage therapy in acute lymphoblastic leukemia in children. Haematologica. 2005; 90:1701-1703.
41. Wadkins RM, Graves DE. Thermodynamics of the interactions of m-AMSA and o-AMSA with nucleic acids: Influence of ionic strength and DNA base composition. Nucleic Acids Res. 1989; 17:9933-9946.
42. Nitiss JL. Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer. 2009; 9:338-350.
43. Roca J, Ishida R, Berger JM, Andoh T, Wang JC. Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp. Proc Natl Acad Sci U S A. 1994; 91:1781-1785.
44. Andoh T, Ishida R. Catalytic inhibitors of DNA topoisomerase II. Biochim Biophys Acta. 1998; 1400:155-171.
45. Shan K, Lincoff AM, Young JB. Anthracycline-induced cardiotoxicity. Ann Intern Med. 1996; 125:47-58.
46. Menna P, Salvatorelli E, Minotti G. Cardiotoxicity of antitumor drugs. Chem Res Toxicol. 2008; 21:978-989.
47. Benes P, Knopfova L, Trcka F, Nemajerova A, Pinheiro D, Soucek K, Fojta M, Smarda J. Inhibition of topoisomerase IIα: Novel function of wedelolactone. Cancer Lett. 2011; 303:29-38.
48. Kang K, Oh SH, Yun JH, Jho EH, Kang JH, Batsuren D, Tunsag J, Park KH, Kim M, Nho CW. A novel topoisomerase inhibitor, daurinol, suppresses growth of HCT116 cells with low hematological toxicity compared to etoposide. Neoplasia. 2011; 13:1043-1057.
49. Li M, Miao ZH, Chen Z, Chen Q, Gui M, Lin LP, Sun P, Yi YH, Ding J. Echinoside A, a new marine-derived anticancer saponin, targets topoisomerase II by unique interference with its DNA binding and catalytic cycle. Ann Oncol. 2009; 21:597-607.
50. Yu Y, Kalinowski DS, Kovacevic Z, Siafakas AR, Jansson PJ, Stefani C, Lovejoy DB, Sharpe PC, Bernhardt PV, Richardson DR. Thiosemicarbazones from the old to new: iron chelators that are more than just ribonucleotide reductase inhibitors. J Med Chem. 2009; 52:5271-5294.
51. Miller MC, 3rd, Bastow KF, Stineman CN, Vance JR, Song SC, West DX, Hall IH. The cytotoxicity of 2-formyl and 2-acetyl-(6-picolyl)-4N-substituted thiosemicarbazones and their copper(II) complexes. Arch Pharm (Weinheim). 1998; 331:121-127.
52. Miller MC, 3rd, Stineman CN, Vance JR, West DX, Hall IH. The cytotoxicity of copper(II) complexes of 2-acetylpyridyl-4N-substituted thiosemicarbazones. Anticancer Res. 1998; 18:4131-4139.
53. Miller MC, Stineman CN, Vance JR, West DX, Hall IH. Multiple mechanisms for cytotoxicity induced by copper(II) complexes of 2-acetylpyrazine-N-substituted thiosemicarbazones. Applied Organometallic Chemistry. 1999; 13:9-19.
54. Zeglis BM, Divilov V, Lewis JS. Role of metalation in the topoisomerase II α inhibition and antiproliferation activity of a series of α-heterocyclic-N4-substituted thiosemicarbazones and their Cu(II) complexes. J Med Chem. 2011; 54:2391-2398.
55. Kongkum N, Tuchinda P, Pohmakotr M, Reutrakul V, Piyachaturawat P, Jariyawat S, Suksen K, Yoosook C, Kasisit J, Napaswad C. DNA topoisomerase II α inhibitory and anti-HIV-1 flavones from leaves and twigs of Gardenia carinata. Fitoterapia. 2011; 83:368-372.
56. Pinto MMM, Sousa ME, Nascimento MSJ. Xanthone derivatives: New insights in biological activities. Curr Med Chem. 2005; 12:2517-2538.
57. Jun KY, Lee EY, Jung MJ, Lee OH, Lee ES, Choo HYP, Na Y, Kwon Y. Synthesis, biological evaluation, and molecular docking study of 3-(3'-heteroatom substituted-2'-hydroxy-1'-propyloxy) xanthone analogues as novel topoisomerase IIα catalytic inhibitor. Eur J Med Chem. 2011; 46:1964-1971.
58. Liu Y, Zhao C, Li H, Yu M, Gao J, Wang L, Zhai Y. Cytotoxicity and apoptosis induced by a new podophyllotoxin glucoside in human hepatoma (HepG2) cells. Can J Physiol Pharmacol. 2010; 88:472-479.